BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Vikas A Gupta,1 James Ackley,2 Jonathan L Kaufman,1 Lawrence H Boise1 1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA; 2Cancer Biology Graduate Program, Winship Cancer Institute of Emory University, E...
Guardado en:
Autores principales: | Gupta VA, Ackley J, Kaufman JL, Boise LH |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e6d2cffa79a14fa8a38bd9e29bf1c781 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013) -
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber M, et al.
Publicado: (2019) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Angelo Maiolino, et al.
Publicado: (2021) -
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
por: Faiman B, et al.
Publicado: (2016)